Sana Biotechnology SANA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -147.4%-76.0pp | -118.7%-19.5pp | -96.1%-3.2pp | -109.1%-38.6pp | -71.4%+5.4pp | |
| Return on invested capital | -157.6%-74.0pp | -130%-15.3pp | -110.1%+2.3pp | -117.4%-32.7pp | -83.6%+9.5pp | |
| Liquidity | ||||||
| Current ratio | 1.3×-2.1× | 1.9×-1.7× | 4.6×+0.1× | 2.5×-2.7× | 3.4×-2.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.2× | 0.5×+0.1× | 0.4×+0.1× | 0.7×+0.4× | 0.4×+0.2× | |
| Per Share | ||||||
| Book value per share | $0.43-51.1% | $0.64-41.4% | $0.75-39.6% | $0.51-64.5% | $0.88-49.0% | |
| Valuation | ||||||
| Market capitalization | $912.8M+55.1% | $1.08B+198% | $913.24M-6.4% | $669.9M-43.5% | $378.04M-80.8% | |
| Price / book | 7.7×+4.8× | 6.7×+5.3× | 4.7×+1.3× | 5.5×+2.0× | 1.8×-3.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sana Biotechnology's ratios come from?
- Every ratio is computed from Sana Biotechnology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.